No megadeals in biotech so far this yr, but on track for record amount >$1 bil deals, 2 biggest deals this yr: $バーテックス ファーマシューティカルズ(VRTX.US)$paid $4.9 bil for$アルパイン イミューン サイエンシズ(ALPN.US)$ $ギリアド サイエンシズ(GILD.US)$paid $4.3 bil for $CBAY Bolt-on deals likely to continue to be the dominant story in 2024, which means we could also see more of this trend... Last yr 84% of M&A deal dollars were for Biotechs w/ Phase 3 & Marketed assets, In the first four months of 2024 56% of M&A deal dollar went towards P...
Deep-pocketed investors have taken a bullish approach towards$ギリアド サイエンシズ(GILD.US)$, Benzinga reported, cited nine extraordinary options activities linked to the stock. About 77% of the trades were leaning bullish and 22% bearish, according to the report. Four of them were puts, totaling $495,628, and five were calls, amounting to $213,111, the report showed. The volume and open interest data on the contract...
$SPDR S&P Biotech ETF(XBI.US)$$iシェアーズ バイオテクノロジー ETF(IBB.US)$ M&A in Q1 alone totaled 12 deals for $19.2 bil which is close to the 10 deals for $21.9 bil in all the 1H of 2023... But one big caveat of this chart, it doesn't include$ファイザー(PFE.US)$'s $43 bil deal for $SGEN announced in Mar 2023 but didn't close until Dec bc of an FTC challenge, The biggest biotech M&A deal so far this yr was$ギリアド サイエンシズ(GILD.US)$'s $4.3 b...
On March 29,$ギリアド サイエンシズ(GILD.US)$and$クシリオ セラピューティクス(XLO.US)$' announced that they have reached an exclusive license agreement totaling more than 600 million US dollars. Here's a look at some technical analysis:
+4
4
2
報告
Pumpui :
Just buy and hold. The gilead news is worth it. Plus any breakthru in cancer treatment for biohealth will be huge. I am holding
Rockaphobicスレ主Pumpui:
Absolutely! I can't help but feel a bit of confidence. With such promising news, coupled with the fact that Vanguard is one of the 52 institutional shareholders. Sign me up! GL!
Gilead Sciences' dividend seems sustainable but flat earnings and high payout could limit future growth. There may be more attractive dividend prospects elsewhere.
The development and marketing of ADCs are likely to significantly benefit the bottom lines of pharmaceutical and biotech companies involved in their production. Companies like ImmunoGen and ADC Therapeutics are also highlighted as ones to watch in the ADC space.
GILD's share price pullback to near 52-week lows could be a buying opportunity. Analysts predict a 5.1% annual earnings growth in the next five years, with a 19.8% upside potential from current levels.
ギリアド サイエンシズに関するコメント
2 biggest deals this yr:
$バーテックス ファーマシューティカルズ(VRTX.US)$ paid $4.9 bil for $アルパイン イミューン サイエンシズ(ALPN.US)$
$ギリアド サイエンシズ(GILD.US)$ paid $4.3 bil for $CBAY
Bolt-on deals likely to continue to be the dominant story in 2024, which means we could also see more of this trend...
Last yr 84% of M&A deal dollars were for Biotechs w/ Phase 3 & Marketed assets,
In the first four months of 2024 56% of M&A deal dollar went towards P...
読み込み中...
Four of them were puts, totaling $495,628, and five were calls, amounting to $213,111, the report showed. The volume and open interest data on the contract...
M&A in Q1 alone totaled 12 deals for $19.2 bil which is close to the 10 deals for $21.9 bil in all the 1H of 2023...
But one big caveat of this chart, it doesn't include $ファイザー(PFE.US)$ 's $43 bil deal for $SGEN announced in Mar 2023 but didn't close until Dec bc of an FTC challenge,
The biggest biotech M&A deal so far this yr was $ギリアド サイエンシズ(GILD.US)$ 's $4.3 b...
$メルク(MRK.US)$ x $イムノバント(IMVT.US)$
$イーライ リリィ(LLY.US)$ x $サイトカイネティックス(CYTK.US)$ (and soon)
$リジェネロン ファーマシューティカルズ(REGN.US)$ x $アペリス ファーマシューティカルズ(APLS.US)$ (panache & brash)
$ギリアド サイエンシズ(GILD.US)$ x % $マドリガル ファーマシューティカルズ(MDGL.US)$ (liver king)
$ブリストル マイヤーズ スクイブ(BMY.US)$ x $アイオバンス バイオセラピューティクス(IOVA.US)$ (cell Tx boost needed)
$イーライ リリィ(LLY.US)$ x $メルス(MRUS.US)$ (partner n...
Here's a look at some technical analysis:
まだコメントはありません